Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEIBA for Reduction of Transfusion in Cardiac Surgery
NCT02577614Phase 1Completed
- Sponsor
- Oregon Health & Science University
- Start
- Feb 2016
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anti-inhibitor coagulant complex in coagulopathy (2 arms), sponsored by Oregon Health & Science University. Primary endpoint: Volume of blood products transfused at 30 days. Started Feb 2016; status: completed.
02
Drugs
anti-inhibitor coagulant complex
03
Conditions
coagulopathy
Beyond the preview
Go deeper on NCT02577614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577614.